For research use only. Not for therapeutic Use.
Amifampridine（Cat No.:I004036）is a potassium channel blocker used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction. By blocking voltage-gated potassium channels, Amifampridine prolongs the duration of action potentials, enhancing the release of acetylcholine at nerve terminals. This improves muscle strength and reduces symptoms such as muscle weakness and fatigue. Amifampridine has shown efficacy in improving motor function and quality of life for patients with LEMS, offering a targeted therapy for managing the symptoms of this challenging neuromuscular condition.
| Catalog Number | I004036 |
| CAS Number | 54-96-6 |
| Molecular Formula | C5H7N3 |
| Purity | 98% |
| Target | Potassium Channel |
| Target Protein | |
| Solubility | DMSO: ≥ 38 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | pyridine-3,4-diamine |
| InChI | InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8) |
| InChIKey | OYTKINVCDFNREN-UHFFFAOYSA-N |
| SMILES | C1=CN=CC(=C1N)N |
| Reference | <p style=/line-height:25px/> |
